SG Americas Securities’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

SG Americas Securities’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-680,739	Closed	-$11.5M	–	3434
2014 Q4	$11.5M	Buy	+680,739	New	+$9.58M	0.06%	344
2014 Q2	–	Sell	-33,473	Closed	-$123K	–	2883
2014 Q1	$123K	Buy	+33,473	New	+$128K	﹤0.01%	2148
2013 Q4	–	Sell	-32,128	Closed	-$136K	–	3357
2013 Q3	$136K	Buy	32,128 +17,014	+113%	+$80.6K	﹤0.01%	2461
2013 Q2	$70K	Buy	+15,114	New	+$52K	﹤0.01%	2145

SG Americas Securities's AVNR Position: Q1 2015 in Review

SG Americas Securities sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 680,739 shares — an estimated $11.5M sold.

SG Americas Securities first reported a position in AVNR in Q2 2013 and held it in 4 quarters. The position peaked at $11.5M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

SG Americas Securities reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
SG Americas Securities sold 680,739 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $11.5M.
SG Americas Securities first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 4 quarters.
SG Americas Securities's AVANIR PHARMACEUTICALS, INC CL A position peaked at $11.5M in Q4 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on SG Americas Securities's 13F filing for Q1 2015, filed 13 May 2015.